Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront in ...
June 1, 2026 06:43 AM EDTUpdated 12:22 PM DealsR&D Lilly enters GLP-2 space in deal with Korea's Hanmi, also forges discovery pact with China's Haisco Reynald Castaneda Deputy Editor Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that